Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Trifluoroacetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL995275 | 0.95 | TP53 (0.30) | TP53 | |
| Trifluoroacetic Acid SCHEMBL4825240 | 0.93 | ALDH1A1 (0.32) | TP53 | |
| Trifluoroacetic Acid SCHEMBL7065544 | 0.88 | — | — | |
| Trifluoroacetic Acid SCHEMBL16394297 | 0.88 | — | — | |
| Trifluoroacetic Acid SCHEMBL21046091 | 0.86 | ATR (0.32) | — | |
| Trifluoroacetic Acid SCHEMBL16288044 | 0.86 | — | — | |
| Trifluoroacetic Acid SCHEMBL21046071 | 0.85 | DPP8 (0.31) | — | |
| Trifluoroacetic Acid SCHEMBL27714775 | 0.84 | TP53 (0.44) | TP53 | |
| Trifluoroacetic Acid SCHEMBL522873 | 0.84 | — | — | |
| Trifluoroacetic Acid SCHEMBL7793452 | 0.82 | TP53 (0.42) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024549-B2 | Compound having affinity substance to soluble protein, cleavable portion and reactive group, or salt thereof | AJINOMOTO CO., INC. (JP) | 2024-07-02 | — | — | US | disclosed |
| US-20210139549-A1 | COMPOUND HAVING AFFINITY SUBSTANCE TO ANTIBODY, CLEAVABLE PORTION, AND REACTIVE GROUP, OR SALT THEREOF | AJINOMOTO CO., INC. (JP) | 2021-05-13 | — | — | US | disclosed |
| EP-3808760-A1 | COMPOUND COMPRISING SUBSTANCE HAVING AFFINITY FOR ANTIBODY, CLEAVAGE SITE AND REACTIVE GROUP, OR SALT THEREOF | AJINOMOTO CO., INC. (JP) | 2021-04-21 | — | — | EP | disclosed |
| US-20200190165-A1 | COMPOUND HAVING AFFINITY SUBSTANCE TO SOLUBLE PROTEIN, CLEAVABLE PORTION AND REACTIVE GROUP, OR SALT THEREOF | AJINOMOTO CO., INC. (JP) | 2020-06-18 | — | — | US | disclosed |
| EP-3617235-A1 | COMPOUND HAVING SUBSTANCE THAT HAS AFFINITY FOR SOLUBLE PROTEIN, CLEAVABLE MOIETY, AND REACTIVE GROUP, OR SALT THEREOF | Ajinomoto Co., Inc. (JP) | 2020-03-04 | — | — | EP | disclosed |
| US-9765114-B2 | Method for cancer immunotherapy | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2017-09-19 | — | — | US | disclosed |
| US-20160168197-A1 | METHOD FOR CANCER IMMUNOTHERAPY | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2016-06-16 | — | — | US | disclosed |
| US-9273148-B2 | Method for cancer immunotherapy | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2016-03-01 | — | — | US | disclosed |
| US-20140046036-A1 | METHOD FOR CANCER IMMUNOTHERAPY | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2014-02-13 | — | — | US | disclosed |
| US-8575308-B2 | Method for cancer immunotherapy | International Institute of Cancer Immunology (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20110229506-A1 | METHOD FOR CANCER IMMUNOTHERAPY | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| US-7939627-B2 | Peptides comprising an epitope of the wilms tumor gene product | International Institute of Cancer Immunology (JP) | 2011-05-10 | — | — | US | disclosed |
| EP-1961761-B1 | NOVEL PEPTIDE COMPOUNDS FROM WILMS' TUMOR | INT INST CANCER IMMUNOLOGY INC (JP) | 2010-10-27 | — | — | EP | disclosed |
| US-20100062010-A1 | NOVEL PEPTIDE COMPOUND | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-1961761-A1 | NOVEL PEPTIDE COMPOUND | International Institute of Cancer Immunology, Inc. (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190165-A1 | COMPOUND HAVING AFFINITY SUBSTANCE TO SOLUBLE PROTEIN, CLEAVABLE PORTION AND REACTIVE GROUP, OR SALT THEREOF | SPPL2B, CSTB, SPPL2A | TP53 2797/4885 |
| US-20160168197-A1 | METHOD FOR CANCER IMMUNOTHERAPY | MET, GZMB, MGMT | TP53 20/4885 |
| US-20100062010-A1 | NOVEL PEPTIDE COMPOUND | NGLY1, MET, ARGLU1 | TP53 51/4885 |
| US-12024549-B2 | Compound having affinity substance to soluble protein, cleavable portion and reactive group, or salt thereof | SPPL2B, CSTB, SPPL2A | TP53 2797/4885 |
| US-20110229506-A1 | METHOD FOR CANCER IMMUNOTHERAPY | MET, GZMB, MGMT | TP53 20/4885 |
| US-20140046036-A1 | METHOD FOR CANCER IMMUNOTHERAPY | MET, GZMB, MGMT | TP53 20/4885 |
| US-20210139549-A1 | COMPOUND HAVING AFFINITY SUBSTANCE TO ANTIBODY, CLEAVABLE PORTION, AND REACTIVE GROUP, OR SALT THEREOF | FCGR3B, FCGR2A, FCGR1A | TP53 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.